Trial
NCT04313881
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Myelodysplastic Syndromes
Intervention
Magrolimab
Why stopped
Study discontinued due to futility based on a planned analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-27